ArticleEmerging microbes & infections2025
Gene-modified genotype II live attenuated African swine fever virus induces cross-protection against genotype I but not against genotype IX.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- African swine fever in the era of global expansion: Epidemiology, transmission dynamics, viral evolution, and One Health control strategies.Veterinary world · 2026Review
- Hope and hurdles: unlocking the potential of modified live virus vaccines for African swine fever.Emerging microbes & infections · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus originated in a wildlife cycle in East Africa and spread to domestic pigs. At least twenty-three genotypes are present in Africa whereas only genotypes I and II have spread to other continents. Vaccine development has been directed mainly to genotype II. The ability of genotype II vaccines to induce cross-protection against other genotypes is unknown. Here, we compared cross-protection induced in pigs by an attenuated multiple gene-deleted genotype II modified live vaccine candidate against challenge with different genotypes. Protection against homologous virulent genotype II virus was 100%. Cross-protection against virulent genotype I virus varied between 57 and 71%. However, no protection was achieved against genotype IX challenge. The results indicate potential for use of vaccines in regions where genotypes I and II are circulating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.